Take a deep dive into our publication digests to learn more about RET inhibitors and their impact on the treatment and management of non-small cell lung cancer (NSCLC) and thyroid cancers.
- Explore the clinical evidence for RET inhibitors
- Discover how testing for RET alterations impacts treatment
- Find out more about molecular screening strategies to detect RET alterations
Identification of NTRK and RET fusion-positive thyroid cancers
Find out more on integrated molecular stratification strategies that can help identify patients who may benefit from RET or NTRK inhibitor treatment.
RET, driver genes, and brain metastases in NSCLC
Next-generation sequencing analysis of a number of potential driver gene mutations uncovered potential risk factors for brain metastases in NSCLC.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer
Explore our publication digest for the evidence of antitumour activity demonstrated by selpercatinib in patients with RET fusion-positive NSCLC, including intracranial response to this targeted treatment.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.